Similarly, when CTCs were identified by flow cytometry as CD45− and positive for markers ASGPR, CD146, and PD-L1, the CTC count before TACE did not influence the tumor recurrence rate and overall survival [39]. The gene discussed is ASGR1; the disease is neoplasm.